f1
Correspondence: Sir Magdi H. Yacoub FRS, Professor of Cardiothoracic Surgery, Heart Science Centre, Imperial College of Science Technology & Medicine, Harefield, Middlesex UB9 6JH, U.K.

References

1
Kannel
WB
, Belanger AJ. Epidemiology of heart failure.
Am Heart J
 .
1992
;
121
:
951
–957
2
Reddy
KS
, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries.
Circulation
 .
1998
;
97
:
596
–601
3
Frazier
OH
, Benedict CR, Radovacevic B. Improved left ventricular function after chronic ventricular unloading.
Ann Thorac Surg
 .
1996
;
62
:
7675
–7682
4
Hetzer
R
, Muller J, Weng Y, Wallukat G, Siegelsberger S, Loebe. Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device.
Ann Thorac Surg
 .
1999
;
68
:
742
–749
5
Sun
BC
, Catanese KA, Spanier TB. 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience.
Ann Thorac Surg
 .
1999
;
68
:
688
–694
6
Mancini
DM
, Beniamovitz A, Levin H. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure.
Circulation
 .
1998
;
98
:
2383
–2389
7
Katz
AM
. Cardiomyopathy of overload, a major development of prognosis in congestive heart failure.
N Engl J Med
 .
1990
;
222
:
100
–110
8
Lorell
BH
, Carabello BA. Left ventricular hypertrophy pathogenesis, detection and prognosis.
Circulation
 .
2000
;
102
:
470
–479
9
Swynghedauw
B
. Molecular mechanisms of myocardial remodelling.
Physiol Rev
 .
1999
;
79
:
216
–261
10
Francis
GS
. Changing the remodelling process in heart failure. Basic mechanisms and laboratory results.
Curr Opin in Cardiol
 .
1998
;
13
:
156
–161
11
Hunter
JJ
, Chien KR. Signalling pathways for cardiac hypertrophy and failure.
N Engl J Med
 .
1999
;
341
:
1276
–1283
12
Sugden
PH
. Signaling in myocardial hypertrophy.
Circ Res
 .
1999
;
84
:
633
–646
13
Onodera
T
, Tamura T, Said S, McCune SA, Gerdes AM. Maladaptive remodelling of cardiac myocyte shape begins long before failure in hypertension.
Hypertension
 .
1998
;
32
:
753
–757
14
Gerdes
AM
, Tamura T, Wang X. Myocyte remodelling during the progression to failure in rats with hypertension.
Hypertension
 .
1996
;
28
:
609
–614
15
Gerdes
AM
, Moore JA, Kellerman SE, Clark LC, Schocker DD. Similar change in cardiac myocyte shape in patients with ischaemic and dilated cardiomyopathy (Abstr).
Circulation
 .
1992
;
86
:
1
–425
16
Gerdes
AM
, Capasso JM. Structural remodelling and mechanical dysfunction of cardiac myocytes in heart failure.
J Mol Cell Cardiol
 .
1995
;
27
:
849
–856
17
Zafeiridis
A
, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support.
Circulation
 .
1998
;
18
:
656
–662
18
Tamura
T
, Said S, Harris J, Lu W, Gerdes AM. Reverse remodelling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system.
Circulation
 .
2000
;
102
:
253
–259
19
Wong
K
, Boheler KR, Bishop J, Petrou M, Yacoub MH. Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features.
Cardiovasc Research
 .
1998
;
37
:
115
–122
20
Wong
K
, Boheler KR, Petrou M, Yacoub MH. Pharmacological modulation pressure overload cardiac hypertrophy changes in ventricular function, extracellular matrix, and gene expression.
Circulation
 .
1997
;
96
:
2239
–2246
21
Petrou
M
, Wynne DG, Boheler KR, Yacoub MH. Clenbuterol induces hypertrophy of the latimus dorsi muscle and heart in the rat with molecular and phenotypic changes.
Circulation
 .
1995
;
92
:
II-483
–II-489
22
Houser
SR
, Lakatta EG. Function of the cardiac myocyte in the conundrum of end-stage, dilated human heart failure.
Circulation
 .
1999
;
341
:
1276
–1283
23
Davies
CH
, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure.
Circulation
 .
1995
;
92
:
2540
–2549
24
Ginsburg
R
, Bristow H, Billingham ME, Stinson EB, Schroeder J, Harrison DC. Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol.
Am Heart J
 .
1983
;
106
:
535
–540
25
Chien
KR
. Stress pathways and heart failure.
Cell
 .
1999
;
98
:
555
–558
26
Schneider
MD
, Schwartz RJ. Chips ahoy: gene expression in hearts surveyed by high-density microarrays.
Circulation
 .
2000
;
102
:
3020
–3027
27
Corbett
JM
, Why HJ, Wheeler CH. Cardiac protein abnormalities in cardiomyopathy detected by two-dimensional polyacrylamide gel electrophoresis.
Electrophoresis
 .
1998
;
19
:
2031
–2042
28
Latif
N
, Khan M, Birks E. Upregulation of the Bcl-2 family of proteins in end-stage heart failure.
J Am Coll Cardiol
 .
2000
;
35
:
1769
–1777
29
Graham
RM
, Owens WA. Pathogenesis of inherited forms of dilated cardiomyopathy.
N Engl J Med
 .
1999
;
341
:
1759
30
Badorff
C
, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Knowlton KU. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy.
Nat Med
 .
1999
;
5
:
320
–326
31
Brown
S
, McGrath MJ, Ooms LM. Characterisation of two isoforms of the skeletal muscle LIM protein 1, SLIM1: localisation of SLIM1 at focal adhesions and the isoform slimmer in the nucleus of myoblasts and cytoplasm of myotubes suggests distinct roles in the cytoskeleton and in nuclear-cytoplasmic communication.
J Biol Chem
 .
1999
;
274
:
27083
–27091
32
Arber
S
, Hunter JJ, Ross J Jr.. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organisation, dilated cardiomyopathy, and heart failure.
Cell
 .
1997
;
88
:
393
–403
33
Zolk
O
, Caroni P, Bohm M. Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure.
Circulation
 .
2000
;
101
:
2674
–2677
34
Minamisawa
S
, Hoshijima M, Chu G. Chronic phospholamban sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy.
Cell
 .
1999
;
99
:
313
–322
35
Spinale
FG
, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function.
Circ Res
 .
1998
;
82
:
482
–495
36
Mann
DL
, Spinale FG. Activation of matrix metalloproteinases in the failing human heart. Breaking the tie that binds. Editorial.
Circulation
 .
1998
;
98
:
1699
–1702
37
Weber
KT
. Targeting pathological remodelling: concepts of cardioprotection and reparation.
Circulation
 .
2000
;
102
:
1342
–1345
38
Brilla
CG
, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.
Circulation
 .
2000
;
102
:
1388
–1393
39
Hafizi
S
, Wharton J, Morgan K. Expression of functional angiotensin-converting enzyme and AT1 receptors in cultured human cardiac fibroblasts.
Circulation
 .
1998
;
98
:
2553
–2559
40
Starling
G
. ACE inhibition in cardiovascular disease.
N Engl J Med
 .
2000
;
342
:
201
–203
41
Pitt
B
. Regression of left ventricular hypertrophy in patients with hypertension. Blockade of the renin-angiotensin-aldosterone system.
Circulation
 .
1998
;
98
:
1987
–1989
42
Cohn
JN
, Levine TB, Olivari MT. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.
N Engl J Med
 .
1984
;
311
:
819
–823
43
Birks
EJ
, Yacoub MH. The role of nitric oxide and cytokines in heart failure.
Cor Art Dis
 .
1997
;
8
:
389
–402
44
Torre-Amione
G
, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD).
J Am Coll Cardiol
 .
1996
;
27
:
1201
–1206
45
Bristow
NR
. Beta-adrenergic receptor in chronic heart failure.
Circulation
 .
2000
;
101
:
558
–569
46
Zaugg
M
, Xu W, Lucchinetti E, Shafig SA, Gamali NZ, Siddiqui MAQ. Beta-adrenergic subtypes differentially affect apoptosis in adult rat ventricular myocytes.
Circulation
 .
2000
;
102
:
344
47
Liggett
SB
, Tepe NM, Lorenz JN. Early and delayed consequences of beta-adrenergic receptor overexpression in mouse hearts. Critical role for expression level.
Circulation
 .
2000
;
101
:
1707
–1714
48
Frantz
S
, Kobzik L, Kim YD. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium.
J Clin Invest
 .
1999
;
104
:
271
–280
49
Wiese
S
, Breyer T, Dragu A. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length.
Circulation
 .
2000
;
102
:
3074
–3079
50
McKelvie
RS
, Yusuf S, Pericak D. Comparison of Candesartan, Enalapril and their combination in congestive heart failure randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot study: The RESOLVD Pilot.
Circulation
 .
1999
;
100
:
1056
–1064
51
Boateng
SY
, Seymour AL, Bhutta NS, Dunn MJ, Yacoub MH, Boheler KR. Sub-anti-hypertensive doses of ramipril normalise sarcoplasmic reticulum calcium ATPase expression and function following cardiac hypertrophy in rats.
J Mol Cell Cardiol
 .
1998
;
30
:
2683
–2694
52
Pitt
B
, Zannand F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
N Engl J Med
 .
1999
;
341
:
709
–717
53
Zannad
F
, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES).
Circulation
 .
2000
;
102
:
2700
–2706
54
Francis
DP
, Shamin W, Davies LC. Cardiopulmonary exercise testing for prognosis in chronic heart failure continuous and independent prognostic value from VE/VCO2slope and peak VO2.
Eur Heart J
 .
2000
;
21
:
154
–161
55
Birks
EJ
, Latif N, Bowles C. Measurement of cytokine levels and activation of the apoptotic pathway in patients requiring Left Ventricular Assist Devices (LVAD): implications for timing of implantation.
Circulation
 .
2000
;
102
:
II-818
56
Owen
VJ
, Burton PB, Michel MC. Myocardial dysfunction in donor hearts. A possible etiology.
Circulation
 .
1999
;
99
:
2565
–2570
57
Birks
EJ
, Burton PB, Owen V. Elevated tumour necrosis factor-alpha and interluekin-6 in myocardium and serum of malfunctioning donor hearts.
Circulation
 .
2000
;
102
:
III352
–8
58
Birks
EJ
, Yacoub MH, Burton P. Activation of apoptotic and inflammatory pathways in dysfunctional donor hearts.
Transplantation
 .
2000
;
70
:
1498
–1506
This content is only available as a PDF.

Comments

0 Comments